Related Experiment Video
Updated: Sep 19, 2025
09:57
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
2.8K
Eslicarbazepine Overdosing in a Teenager: Case Description and Management
Maria Kavga1, Jobst Rudolf2, Foteini Mitsa3
14th Department of Pediatrics, Medical School (MK,MF,PP), Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece.
Summary
Eslicarbazepine acetate overdose in adolescents is rare but can cause neurological toxicity. Treatment involves diuretics for kidney clearance and medications like haloperidol and midazolam for agitation management.
Area of Science:
- Pharmacology
- Neurology
- Adolescent Medicine
Background:
- Eslicarbazepine acetate is a newer anti-epileptic drug approved for adolescent use.
- Limited data exists on eslicarbazepine acetate dosing and overdose in adolescents.
Purpose of the Study:
- To report a rare case of intentional eslicarbazepine acetate overdose in a healthy teenager.
- To describe the clinical presentation and management of neurological toxicity following overdose.
Main Methods:
- Case report of an adolescent with intentional eslicarbazepine acetate overdose.
- Management included supportive care, hyperhydration with diuretics, haloperidol for agitation, and midazolam for symptom control.
Main Results:
- The patient presented with neurological toxicity after intentional overdose.
- Treatment with diuretics, haloperidol, and midazolam facilitated rapid drug clearance and managed agitation.
Conclusions:
- Eslicarbazepine acetate overdose can lead to significant neurological toxicity in adolescents.
- Aggressive management including diuretics and sedatives can be effective in managing overdose symptoms and enhancing elimination.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
289
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
289
01:24Mania and Antimanic Drugs: Overview
328
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
328
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
461
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
461
01:24Epilepsy and Seizures: Overview
296
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
296
01:26Psychosis: Goals of Pharmacotherapy
214
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
214
01:26Anticholinesterase Agents: Poisoning and Treatment
1.0K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.0K